









Märkte
/
Aktien
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

133.280USD

+0.560+0.42%

Trading geöffnet （ET）Kurse um 15 Minuten verzögert

2.57BMarktkapitalisierung

VerlustKGV TTM



Ligand Pharmaceuticals Inc

133.280

+0.560+0.42%

Übersicht Unternehmen Finanzen

Finanzen

mehr Informationen über Ligand Pharmaceuticals Inc Unternehmen

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Unternehmensinformationen

BörsenkürzelLGND

Name des UnternehmensLigand Pharmaceuticals Inc

IPO-datumNov 18, 1992

CEOMr. Todd C. Davis

Anzahl der mitarbeiter68

WertpapierartOrdinary Share

GeschäftsjahresendeNov 18

Addresse555 Heritage Drive, Suite 200

StadtJUPITER

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl33458

Telefon18585507500

Websitehttps://www.ligand.com/

BörsenkürzelLGND

IPO-datumNov 18, 1992

CEOMr. Todd C. Davis

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

+14.86%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.29K

+31.26%

Mr. Todd C. Davis

Chief Executive Officer, Director

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Jason M. Aryeh

Independent Director

137.16K

+0.89%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

45.30K

-2.02%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

17.05K

-4.31%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Captisol

13.46M

29.69%

Qarziba

5.44M

12.00%

Filspari

5.30M

11.69%

Kyprolis

4.72M

10.42%

Milestone

4.38M

9.67%

Other

12.02M

26.52%

Aktionärsstatistik

Aktualisiert: Fri, May 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

13.86%

The Vanguard Group, Inc.

10.63%

Janus Henderson Investors

5.33%

Macquarie Investment Management

4.70%

Dimensional Fund Advisors, L.P.

3.86%

Other

61.62%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

57.94%

Investment Advisor/Hedge Fund

37.89%

Individual Investor

2.39%

Research Firm

1.84%

Pension Fund

1.60%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.28%

Hedge Fund

0.05%

Insurance Company

0.03%

Institutionelle Beteiligung

Aktualisiert: Tue, Jul 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q2

534

19.71M

102.14%

-793.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

2023Q1

528

16.47M

96.50%

-1.33M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

2.67M

13.86%

-26.33K

-0.97%

Mar 31, 2025

The Vanguard Group, Inc.

2.05M

10.63%

-29.89K

-1.44%

Mar 31, 2025

Janus Henderson Investors

1.03M

5.33%

+12.53K

+1.23%

Mar 31, 2025

Macquarie Investment Management

906.23K

4.7%

+21.85K

+2.47%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

744.93K

3.86%

+21.91K

+3.03%

Mar 31, 2025

State Street Global Advisors (US)

727.13K

3.77%

-16.51K

-2.22%

Mar 31, 2025

Congress Asset Management Company, LLP

642.71K

3.33%

+21.23K

+3.42%

Mar 31, 2025

Stephens Investment Management Group, LLC

607.22K

3.15%

-5.56K

-0.91%

Mar 31, 2025

Chicago Capital, LLC

554.52K

2.87%

+2.93K

+0.53%

Mar 31, 2025

Geode Capital Management, L.L.C.

464.45K

2.41%

+26.01K

+5.93%

Mar 31, 2025

Verbundene ETFs

Aktualisiert: Sat, Aug 2

Name

Anteil

Invesco Pharmaceuticals ETF

3.03%

Virtus LifeSci Biotech Products ETF

1.91%

SPDR S&P Pharmaceuticals ETF

1.86%

Franklin Genomic Advancements ETF

1.68%

Invesco S&P SmallCap Health Care ETF

1.57%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.34%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.32%

iShares U.S. Pharmaceuticals ETF

1.1%

First Trust Multi-Manager Small Cap Opportunities ETF

0.71%

Simplify Health Care ETF

0.52%

Invesco Pharmaceuticals ETF

Anteil3.03%

Virtus LifeSci Biotech Products ETF

Anteil1.91%

SPDR S&P Pharmaceuticals ETF

Anteil1.86%

Franklin Genomic Advancements ETF

Anteil1.68%

Invesco S&P SmallCap Health Care ETF

Anteil1.57%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Anteil1.34%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil1.32%

iShares U.S. Pharmaceuticals ETF

Anteil1.1%

First Trust Multi-Manager Small Cap Opportunities ETF

Anteil0.71%

Simplify Health Care ETF

Anteil0.52%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI

